Autoimmune Disease Treatment Market Analysis & Forecast: 2026-2033

Autoimmune Disease Treatment Market Size and Share Analysis- 2026 To 2033

The Autoimmune Disease Treatment Market size is anticipated to grow at a CAGR of 7.6%, with a market value of USD 8.14 Bn in 2026 and is expected to reach USD 13.60 Bn by 2033. The primary drivers are largely defined by the rising prevalence of autoimmune disorders, increasing diagnosis rates, growing adoption of biologic and targeted therapies, and continued advancements in immunomodulatory treatment approaches. The growing cases of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel diseases, systemic lupus erythematosus, and type 1 diabetes are providing further impetus to the need for long-term therapy options. As per the reports published by the National Institutes of Health (NIH), around 23.5 million to 50 million people in America are affected by autoimmune diseases.

Key Takeaways

• The organ-specific autoimmune disease segment is anticipated to hold the largest market share with 65.0% in 2026. The growth of the segment can be attributed to the high burden of treatment related to organ specific autoimmune diseases, such as type 1 diabetes, multiple sclerosis, autoimmune thyroid diseases, and inflammatory bowel diseases, along with rising incidences and the need for continued treatment. As per the report of the International Diabetes Federation (IDF), there were 1.8 million children and adolescents under the age of 20 years suffering from type 1 diabetes worldwide in 2025.
• The anti-inflammatory drugs segment is set to lead with approximately 37.0% in 2026. The segment’s growth is owing to the extensive use of TNF inhibitors, interleukin-targeting therapies, JAK inhibitors, and other anti-inflammatory agents across rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other immune-mediated disorders. The U.S. FDA approved the first interchangeable biosimilars to Simponi and Simponi Aria in 2026 for indications including rheumatoid arthritis and ulcerative colitis, demonstrating continued expansion of anti-inflammatory biologic treatment options.
• The North America segment is likely to dominate the market with approximately 43.0% in 2026. The region’s growth is owing to the high adoption of biologics and targeted therapies, advanced specialty-care infrastructure, strong pharmaceutical research and development activity, favorable treatment access, and substantial healthcare and prescription-drug expenditure, particularly in the U.S. NIH Office of Autoimmune Disease Research announced eight collaborative research awards in March 2026, involving 21 principal investigators, 11 NIH institutes and centers, and research across 19 autoimmune diseases, highlighting the region’s strong autoimmune research ecosystem

Market Drivers

Rising Autoimmune Disease Burden and Diagnostic Gaps are Expanding Long-Term Treatment Demand

The Autoimmune Disease Treatment Market is being driven by the broad and increasing clinical burden of chronic autoimmune disorders. Conditions such as rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, myasthenia gravis, and autoimmune thyroid disorders frequently require prolonged or lifelong pharmacological management, supporting recurring demand for immunosuppressants, anti-inflammatory agents, corticosteroids, and targeted therapies.

According to the NIH-Wide Strategic Plan for Autoimmune Diseases Research, FY 2026-2030, there are over 140 autoimmune diseases known, whereas about 25% of people having autoimmune disease have multiple autoimmune conditions. Also, as mentioned by the NIH, roughly 50% of patients having autoimmune diseases get diagnosed late, pointing out considerable unmet needs in diagnosing and initiating treatment for such patients.

Development of Targeted Biologics is Transforming Autoimmune Disease Treatment

The treatment landscape is moving away from general immune suppression and toward approaches that target antibodies, cytokines, receptors, B-cell pathways, and other immune system components specific to the disease. Such treatment could offer alternative therapy options for patients who are poorly responsive to standard steroids or immunosuppressants.

In April 2025, the U.S. Food and Drug Administration approved Imaavy (nipocalimab-aahu), an FcRn inhibitor, for the treatment of generalized myasthenia gravis in adults and pediatric patients aged 12 years and above with eligible autoantibody-positive disease. This drug approval is based on the clinical data generated from 196 adult patients at 82 clinical trial centers in 17 countries.

Current Events and Their Impact on the Autoimmune Disease Treatment Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Why are Organ-specific Autoimmune Diseases Acquiring the Largest Share?

On the basis of disease type, the organ-specific autoimmune diseases segment is projected to account for the largest Autoimmune Disease Treatment Market share of approximately 65.0% in 2026. The segment’s dominance is owing to the substantial treatment burden associated with diseases affecting specific organs and tissues, including multiple sclerosis, inflammatory bowel diseases, autoimmune thyroid diseases, type 1 diabetes, and autoimmune dermatological disorders. These conditions frequently require long-term disease control, repeat prescriptions, and escalating treatment from conventional drugs to targeted immunomodulators and biologics.

Furthermore, a 2025 Nature Reviews Gastroenterology & Hepatology assessment concluded that inflammatory bowel disease prevalence continues to accumulate globally and projected that more than 1% of the population in early-industrialized countries could be living with IBD within the next decade. The expanding burden of organ-focused chronic inflammatory diseases is therefore strengthening recurring demand for long-duration pharmacological treatment.

In June 2026, the European Commission authorized Sanofi’s Cenrifki (tolebrutinib) for adults with secondary progressive multiple sclerosis without relapses during the previous two years.

Anti-inflammatory Drugs Hold the Largest Market Share 

To learn more about this report, Request Free Sample

On the basis of drug type, the anti-inflammatory drugs segment is projected to lead with approximately 37.0% of the Autoimmune Disease Treatment Market in 2026. The segment’s growth is owing to the broad use of inflammation-targeting therapies across rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, and other immune-mediated conditions.

A 2025 systematic review and meta-analysis covering 45 records found that the JAK inhibitor upadacitinib demonstrated efficacy across five major immune-mediated inflammatory diseases. In ulcerative colitis, upadacitinib increased clinical remission versus placebo by a risk ratio of 6.92, while in Crohn’s disease the corresponding clinical-remission risk ratio was 2.47.

In July 2026, AbbVie announced European Commission approval of RINVOQ (upadacitinib) for adults and adolescents aged 12 years and older with non-segmental vitiligo who are candidates for systemic therapy.

Autoimmune Disease Treatment Market Trends

• The increasing shift toward highly targeted oral therapies is changing autoimmune disease treatment by providing biologic-like pathway specificity with the convenience of oral administration. In March 2026, the U.S. FDA approved Johnson & Johnson’s ICOTYDE (icotrokinra), the first targeted oral peptide blocking the IL-23 receptor for moderate-to-severe plaque psoriasis. Its four Phase III studies included approximately 2,500 patients, with around 70% achieving clear or almost clear skin and 55% achieving PASI 90 at Week 16.
• The growing adoption of self-administered biologic therapies is shifting autoimmune treatment away from hospital- and infusion-center-dependent delivery toward more convenient home-based management. In April 2026, AstraZeneca’s Saphnelo Pen received U.S. approval as a once-weekly self-administered autoinjector for systemic lupus erythematosus. More than 40,000 patients globally had already been treated with Saphnelo, supporting the commercial transition of established autoimmune biologics toward patient-friendly delivery formats.
• The emerging use of CAR-T cell therapy for immune-system resetting is creating a potential shift from lifelong immune suppression toward durable, treatment-free remission in severe autoimmune diseases. A 2026 Nature Medicine Phase I/II CASTLE trial involving 24 treatment-refractory patients with lupus, systemic sclerosis, and inflammatory myopathies found that 22 of 24 achieved predefined efficacy endpoints. Nine of 10 lupus patients achieved DORIS remission, while all 24 remained free from glucocorticoids and other immunosuppressive treatments throughout the 24-week observation period.

Regional Insights 

To learn more about this report, Request Free Sample

North America Dominates Owing to Advanced Treatment Access and Strong Biopharmaceutical Innovation

The North America region is projected to account for approximately 43.0% of the Autoimmune Disease Treatment Market in 2026. The region’s dominance is owing to the high adoption of biologics and targeted immunotherapies, advanced rheumatology and specialty-care infrastructure, strong pharmaceutical R&D activity, and rapid regulatory uptake of novel treatments for complex autoimmune diseases.

The region continues to witness the introduction of first-in-class autoimmune therapies. In April 2025, the U.S. FDA approved Amgen’s UPLIZNA (inebilizumab-cdon) as the first and only approved treatment for adults with IgG4-related disease. In the Phase III MITIGATE trial, UPLIZNA produced an 87% reduction in the risk of disease flare compared with placebo, while 57.4% of treated patients achieved flare-free, treatment-free complete remission at Week 52 compared with 22.4% receiving placebo.

In July 2026, Novartis announced that the U.S. FDA granted traditional approval to Fabhalta (iptacopan) for slowing kidney-function decline in adults with primary IgA nephropathy (IgAN) at risk of disease progression.

Asia Pacific Autoimmune Disease Treatment Market Trends

Asia Pacific is expected to be the fastest-growing region in the Autoimmune Disease Treatment Market, with an estimated CAGR of approximately 8.46% over the forecast period. The region’s growth is owing to the expanding availability of biologics and biosimilars, growing specialty-care infrastructure, rising diagnosis of autoimmune and immune-mediated diseases, increasing domestic biopharmaceutical development, and broader regulatory approval of targeted therapies in China, Japan, South Korea, and other major markets.

China is rapidly expanding its portfolio of locally developed immune-targeted treatments. In 2025, China’s National Medical Products Administration approved Vunakizumab from Suzhou Suncadia Biopharmaceuticals and Xeligekimab from Chongqing Genrix Biopharmaceutical for adults with moderate-to-severe plaque psoriasis requiring systemic treatment or phototherapy.

In June 2026, Takeda announced approval in Japan for Kenketsu Glovenin-I 10% IV and Glovenin-I 10% IV for autoimmune encephalitis. Takeda stated that these became the first treatments approved in Japan specifically for autoimmune encephalitis.

Advanced Cell-Therapy Pipeline and Rapid Clinical Translation are Accelerating the Autoimmune Disease Treatment Market in the United States

The U.S. Autoimmune Disease Treatment Market is witnessing strong growth owing to the high adoption of advanced biologics, increasing development of cell-based immune-reset therapies, strong specialty-care infrastructure, and rapid clinical translation of novel treatments for refractory autoimmune diseases.

In April 2026, U.S.-based Kyverna Therapeutics reported pivotal Phase II results for mivocabtagene autoleucel (miv-cel) in stiff person syndrome. Among 26 treated patients, 81% achieved a clinically meaningful improvement in walking speed at Week 16, while 67% of patients who required walking assistance at baseline no longer needed it by Week 16. All 26 patients also remained free from chronic immunotherapies through the assessed follow-up period.

China Autoimmune Disease Treatment Market Trends

China is expected to witness strong growth in the Autoimmune Disease Treatment Market owing to the rapid development of domestically produced biologics, expanding targeted immune therapies, regulatory reforms supporting innovative drug approvals, and increasing treatment availability for chronic immune-mediated diseases.

In November 2025, Innovent Biologics received NMPA approval for PECONDLE (picankibart), making it the first domestically developed IL-23p19 monoclonal antibody approved in China for moderate-to-severe plaque psoriasis. Innovent estimates that more than 7 million people in China are living with psoriasis. In the pivotal Phase III CLEAR-1 study, more than 80% of patients achieved PASI 90 at Week 16, while maintenance dosing is required only once every 12 weeks.

Who are the Major Companies in Autoimmune Disease Treatment Industry

Some of the major key players in Autoimmune Disease Treatment Market are Johnson & Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Active Biotech, GlaxoSmithKline plc, Eli Lilly and Company, AutoImmune Inc., Pfizer, Inc. AstraZeneca plc, Lupin Limited, 4SC AG, Amgen, Inc., and Bristol-Myers Squibb.

Key News

• In March 2026, Roche announced positive Phase III FENhance 1 results for fenebrutinib in relapsing multiple sclerosis. Fenebrutinib reduced annualized relapse rates by 51% versus teriflunomide, while the companion FENhance 2 study showed a 59% reduction.
• In February 2026, Lilly announced positive Phase IIIb TOGETHER-PsO results evaluating Taltz plus Zepbound in patients with moderate-to-severe psoriasis and obesity/overweight. At Week 36, 40.6% achieved complete skin clearance (PASI 100) with the combination versus 29.0% with Taltz alone.

Market Report Scope

Analyst Opinion

• The Autoimmune Disease Treatment Market is expected to benefit from a large, clinically diverse patient base and increasing recognition of autoimmune comorbidity. A large U.S. electronic-health-record study published in the Journal of Clinical Investigation estimated that more than 15 million people, or 4.6% of the U.S. population, have at least one autoimmune disease, while 34% of diagnosed patients have more than one autoimmune condition. This supports sustained demand for long-term, multi-mechanism treatment strategies rather than single-disease therapeutic approaches.
• The market is increasingly moving beyond conventional corticosteroids and broad immunosuppression toward immune-reset approaches such as CAR-T cell therapy. A May 2026 Nature Medicine review highlighted the rapid translation of CAR-based cellular therapies into autoimmune diseases, particularly systemic lupus erythematosus, systemic sclerosis, inflammatory myopathies, and other severe antibody-mediated disorders. This emerging treatment class has the potential to shift selected patients from continuous drug administration toward deeper and potentially durable immune remission.
• Non-pharmaceutical immune modulation is also beginning to expand the competitive treatment landscape. In July 2025, the U.S. FDA approved SetPoint Medical's SetPoint System for adults with moderate-to-severe rheumatoid arthritis who have not responded adequately to biologic or targeted synthetic DMARDs. The approval was supported by the 242-patient RESET-RA study, and SetPoint reported that 75% of study patients were free from biologic or targeted synthetic DMARDs at 12 months. This demonstrates that future autoimmune disease management could increasingly combine pharmaceuticals, biologics, cell therapies, and bioelectronic approaches.

Market Segmentation

• By Disease Type (Revenue, USD Bn, 2021-2033)
  • Systemic
  • Organ-specific
• By Drug Type (Revenue, USD Bn, 2021-2033)
  • Immunosuppressant’s
  • Anti-Inflammatory Drugs
  • Corticosteroids
  • Nonsteroidal anti-inflammatory drugs
  • Others
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Rheumatologists and immunologists
• Gastroenterologists, neurologists, and dermatologists
• Autoimmune disease specialists and treating physicians
• Pharmaceutical and biotechnology R&D heads
• Clinical development and medical affairs professionals
• Hospital and specialty-clinic procurement managers
• Biologics and biosimilar manufacturers
• Key opinion leaders (KOLs) in autoimmune and inflammatory diseases

Databases

• World Health Organization (WHO)
• National Institutes of Health (NIH)
• U.S. Centers for Disease Control and Prevention (CDC)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• ClinicalTrials.gov
• Organisation for Economic Co-operation and Development (OECD)
• World Bank

Magazines

• Fierce Pharma
• BioPharma Dive
• Pharmaceutical Technology
• PharmaTimes
• The Pharmaceutical Journal
• Drug Discovery & Development

Journals

• Nature Reviews Rheumatology
• The Lancet Rheumatology
• Arthritis & Rheumatology
• Annals of the Rheumatic Diseases
• Autoimmunity Reviews
• Journal of Autoimmunity
• Clinical Immunology
• Frontiers in Immunology

Newspapers

• Reuters
• The Wall Street Journal
• Financial Times
• The New York Times
• Bloomberg
• The Economic Times

Associations

• American College of Rheumatology (ACR)
• European Alliance of Associations for Rheumatology (EULAR)
• Lupus Foundation of America
• Multiple Sclerosis International Federation (MSIF)
• Crohn’s & Colitis Foundation
• Breakthrough T1D
• International Autoimmune Hepatitis Group
• Autoimmune Association

Public Domain Sources

• Company Annual Reports and Investor Presentations
• Pharmaceutical Company Press Releases and Pipeline Updates
• FDA Drug Approvals, Labels, and Regulatory Review Documents
• EMA Assessment Reports and Regulatory Decisions
• Clinical Trial Registries and Published Trial Results
• Government Epidemiology and Healthcare Expenditure Reports
• Peer-reviewed Autoimmune Disease Epidemiology Studies
• Treatment Guidelines from Professional Medical Associations
• Patent Databases such as WIPO, USPTO, and Google Patents

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 10 Years